SHAREHOLDER ALERT: WeissLaw LLP Reminds FIII, JWS, BRPA, and CGIX Shareholders About Its Ongoing Investigations

NEW YORK, Jan. 7, 2021 /PRNewswire/ --

If you own shares in any of the companies listed above and
would like to discuss our investigations or have any questions concerning
this notice or your rights or interests, please contact:

Joshua Rubin, Esq.
WeissLaw LLP
1500 Broadway, 16^th Floor
New York, NY  10036
(212) 682-3025
(888) 593-4771
stockinfo@weisslawllp.com

Forum Merger III Corporation (NASDAQ: FIII)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Forum Merger III Corporation (NASDAQ: FIII) in connection with the company's proposed merger with Electric Last Mile, Inc. ("ELMI").  Under the terms of the merger agreement, FIII will acquire ELMI through a reverse merger that will result in ELMI becoming a publicly listed company.  If you own FIII shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website:  https://weisslawllp.com/fiii/   

Jaws Acquisition Corp. (NYSE: JWS)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Jaws Acquisition Corp. (NYSE: JWS) in connection with the company's proposed merger with Cano Health, LLC ("Cano").  Under the terms of the merger agreement, JWS will acquire Cano through a reverse merger that will result in Cano becoming a publicly traded company.  If you own JWS shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website:  https://weisslawllp.com/jws/

Big Rock Partners Acquisition Corp. (NASDAQ: BRPA)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Big Rock Partners Acquisition Corp. (NASDAQ: BRPA) in connection with the company's proposed merger with NeuroRx, Inc. ("NeuroRx").  Under the terms of the agreement, BRPA will acquire NeuroRx through a reverse merger, with NeuroRx surviving as the new publicly traded company.  If you own BRPA shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://www.weisslawllp.com/brpa/

Cancer Genetics, Inc. (NASDAQ: CGIX)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Cancer Genetics, Inc. (NASDAQ: CGIX) in connection with the company's proposed merger with privately held StemoniX, Inc. ("StemoniX").  Under the terms of the agreement, CGIX will acquire all of the outstanding shares of StemoniX in exchange for approximately 78% of CGIX's outstanding common stock.  The combined company will continue to trade on the NASDAQ, but CGIX shareholders will control only 22% of the surviving entity.  If you own CGIX shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://www.weisslawllp.com/cgix

View original content to download multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-weisslaw-llp-reminds-fiii-jws-brpa-and-cgix-shareholders-about-its-ongoing-investigations-301203012.html

SOURCE WeissLaw LLP